Press Releases

Hetero Labs Limited acquires Tarbis Farma, in Spain

India, Hyderabad, 2 nd January 2019: Hetero, one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs, announced today that its European subsidiary Amarox Limited has acquired Tarbis Farma, S.L.U., a company operating in Spain from Grupo Ferrer Internacional, S.A.

Tarbis Farma comes with a robust product portfolio and an extensive marketing network with well-experienced personnel in Retail business across Spain. The acquisition enables Hetero with a strong front-end marketing presence giving Amarox the required commercial infrastructure, product portfolio, manpower and a seamless entry into the Retail, Hospital and Tender business channels in Spain.

Mr. A V Narasa Reddy, Executive Director of Hetero Labs Limited, stated that this acquisition fits very well with Hetero’s growth strategy in EU giving Amarox a platform to reach out to the customers in a robust way with the present portfolio and Hetero’s pipeline of products.

The buyer and seller were advised by Crowe and Deloitte respectively.

About Hetero

Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs. Backed by 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, generics, biosimilars, custom pharmaceutical services and branded generics. The company is globally recognized for its strengths in Research and Development, manufacturing and commercialization of a wide range of products.

Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, approved by stringent global regulatory authorities. Our portfolio includes 300 plus products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology and Immunology etc.

Hetero has a strong global presence in over 126 countries and focusses on making affordable medicines accessible to patients worldwide. For more information on Hetero, please visit

Media Contact:

Jeyasingh Balakrishnan
Head – Corporate Communications
Hetero Labs Limited, India
Mobile: +91 9989626541/ +91 9833836185